Evaluation of ivabradine in left ventricular dyssynchrony and reverse remodeling in patients with chronic heart...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Heart failure (HF) is a complex condition often characterized by impaired cardiac function and rhythm abnormalities.
• Ivabradine is a selective heart rate-lowering agent primarily used in patients with symptomatic chronic heart failure (HF) and a heart rate of at least 70 bpm in sinus rhythm.
• Cardiac dyssynchrony is a common finding in HF patients and contributes to disease progression and poor outcomes.

Purpose of the Study:

• To investigate the impact of ivabradine on cardiac dyssynchrony parameters in patients with chronic systolic heart failure and sinus rhythm.
• To evaluate changes in interventricular dyssynchrony, septal to posterior wall motion delay, and septal to lateral Ts delay.
• To assess the effect of ivabradine on left ventricular volumes and ejection fraction.

Main Methods:

• A study involving 55 patients with heart failure receiving standard medication, with 32 completing the study.
• Group I patients received ivabradine in addition to their existing heart failure medication.
• Echocardiographic measurements of dyssynchrony, left ventricular volumes, and ejection fraction were recorded at baseline, 1 month, and 3 months.

Main Results:

• Ivabradine treatment led to significant improvements in cardiac dyssynchrony parameters.
• Interventricular dyssynchrony (IVD) decreased from 42.0 ± 24.4 ms at baseline to 30.7 ± 19.4 ms at 3 months (P < .001).
• Left ventricular end-systolic volume (LVESV) significantly decreased from 139.4 ± 42.2 mL at baseline to 123.3 ± 39.5 mL at 3 months (P < .001).

Conclusions:

• The addition of ivabradine to standard heart failure treatment significantly improves cardiac dyssynchrony in patients with chronic systolic heart failure and sinus rhythm.
• Ivabradine demonstrates a beneficial effect on mechanical dyssynchrony, potentially contributing to improved cardiac function in this patient population.
• These findings suggest a role for ivabradine in managing cardiac dyssynchrony beyond its heart rate-lowering effect.